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Background: We aimed to establish a bipolar disorder biobank to serve as a resource for clinical and biomarker
studies of disease risk and treatment response. Here, we describe the aims, design, infrastructure, and research
uses of the biobank, along with demographics and clinical features of the first participants enrolled.
Methods: Patients were recruited for the Mayo Clinic Bipolar Biobank beginning in July 2009. The Structured Clinical
Interview for DSM-IV was used to confirm bipolar diagnosis. The Bipolar Biobank Clinical Questionnaire and Participant
Questionnaire were designed to collect detailed demographic and clinical data, including clinical course of illness
measures that would delineate differential phenotypes for subsequent analyses. Blood specimens were obtained
from participants, and various aliquots were stored for future research.
Results: As of September 2014, 1363 participants have been enrolled in the bipolar biobank. Among these first
participants, 69.0 % had a diagnosis of bipolar disorder type I. The group was 60.2 % women and predominantly
white (90.6 %), with a mean (SD) age of 42.6 (14.9) years. Clinical phenotypes of the group included history of
psychosis (42.3 %), suicide attempt (32.5 %), addiction to alcohol (39.1 %), addiction to nicotine (39.8 %), obesity
(42.9 %), antidepressant-induced mania (31.7 %), tardive dyskinesia (3.2 %), and history of drug-related serious
rash (5.7 %).
Conclusions: Quantifying phenotypic patterns of illness beyond bipolar subtype can provide more detailed clinical
disease characteristics for biomarker research, including genomic-risk studies. Future research can harness clinically
useful biomarkers using state-of-the-art research technology to help stage disease burden and better individualize
treatment selection for patients with bipolar disorder.
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Bipolar disorder is a medical illness characterized by re-
current episodes of mania or hypomania and major de-
pression (Kraepelin 1921; Goodwin and Jamison 2007).
Historically, the lifetime prevalence has been reported
as ≈1 %, and the standard treatment, lithium, has been
adequate. However, in the past 20 years, increasing evi-
dence has suggested higher prevalence rates (up to 5 %,* Correspondence: mfrye@mayo.edu
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provided the original work is properly creditedincluding subsyndromal diagnostic criteria) and has
shown subgroups with differential response to alterna-
tive mood-stabilizing treatments (Kessler et al. 2005;
Frye 2011).
Bipolar disorder is highly heritable, and additive gen-
etic effects can account for up to 85 % of the variance in
risk (Bienvenu et al. 2011). However, not all disease-risk
genes have been fully identified. Recent genome-wide as-
sociation studies have identified several relatively diverse
risk genes, including Ankyrin-G or ANK3 (encoding anky-
rin 3) (Ferreira et al. 2008), NCAN (encoding neurocan)
(Cichon et al. 2011), DGKH (encoding diacylglycerole distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
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calcium channel) (Ferreira et al. 2008; Sklar et al. 2008),
ODZ4 (human homologue of Drosophila gene) (Psychiatric
GWAS Consortium Bipolar Disorder Working Group
2011), TRANK1 (tetratricopeptide repeat and ankyrin re-
peat containing 1) (Mühleisen et al. 2014), and ADCY2
(adenylate cyclase 2) (Mühleisen et al. 2014). Further
investigation has also focused on enriched samples (e.g.,
pediatric cohorts with early-onset disease and positive fam-
ily history), which has identified candidate genes such as
the clock gene RORB (RAR-related orphan receptor beta)
(McGrath et al. 2009). Further research using large collec-
tions of patients with precisely defined phenotypes and
high-quality specimens, which are noted barriers to effect-
ive clinical translation (Olson et al. 2013), can potentially
improve clinical management of bipolar disorder by devel-
oping genetic testing for disease risk and pharmacogenomic
testing to guide treatment.
Mayo Clinic, in collaboration with the Lindner Center
of HOPE and the University of Minnesota, established a
bipolar disorder biobank. The biobank uses state-of-the-
art research technology to allow for both clinical and
biomarker studies of bipolar disease risk and treatment
response. This article describes (1) the aims, design, and
infrastructure of the bipolar biobank; (2) demographics
and clinical features of the first 1363 participants en-




The Mayo Clinic Bipolar Biobank was initiated in 2009;
key collaborating sites included the Lindner Center of
HOPE/University of Cincinnati and the University of
Minnesota. The co-principal investigators (M.A.F. and
J.M.B.) provide administrative oversight, along with the
biobank’s executive committee, the Mayo Clinic Biospe-
cimen Trust Oversight Group, and the Center for Indi-
vidualized Medicine (Olson et al. 2013).
Recruitment and informed consent
Enrollment sites, each with site-specific institutional re-
view board approval, included Mayo Clinic, Rochester,
Minnesota; Lindner Center of HOPE/University of
Cincinnati College of Medicine, Cincinnati, Ohio; and
the University of Minnesota, Minneapolis, Minnesota.
Potential participants were identified through various
methods, including routine clinical appointments, in-
patients admitted in mood disorder units, and recruit-
ment advertising. Participants were required to be be-
tween 18 and 80 years old and be able to speak English,
provide inform consent, and have DSM-IV-TR diagnostic
confirmation of type I or II bipolar disorder or schizoaffec-
tive bipolar disorder (American Psychiatric Association2000). Patients with active psychosis or active suicidal idea-
tion were not invited to participate in the biobank. The
written informed consent process was followed by a com-
prehension test questionnaire to ensure key points of study
participation were understood (i.e., longevity of DNA sam-
ple, deidentified samples in studies within and outside of
primary institution, potential conflict of interest, Frye et al.
2015b).
Demographic and clinical data collection
Tools used to evaluate the participants included the
Structured Clinical Interview for DSM-IV (SCID) mod-
ules A, D, and overview, a Bipolar Biobank clinical ques-
tionnaire designed to assess clinical variables such as
course of the illness, past treatments and response rates,
and psychiatric or medical comorbid conditions, and a
Bipolar Biobank participant questionnaire for demo-
graphic characteristics (e.g., marital status, race and eth-
nicity, education, and occupational functioning level),
family history, and current substance use.
Course of illness measures were collected and focused
on the phenotype domains of psychosis, suicidality,
mood instability, comorbid anxiety, and comorbid sub-
stance abuse. A participant was positive for psychosis if
he or she had a lifetime history of hallucinations or delu-
sions, specified in mania, depression, or both or outside
of episodes. Suicidality was designated as positive if the
patient had one or more attempts requiring medical
intervention. Mood instability was a composite sum
(range, 0–5) of the lifetime presence (yes = 1, no = 0) of
five features: mixed episodes, rapid cycling, ultrarapid/
ultradian cycling, cycle acceleration over time, and in-
creased severity of episodes over time. Comorbid anxiety
was a similar composite sum (range, 0–6) of the lifetime
presence of six features: posttraumatic stress disorder,
generalized anxiety disorder, social anxiety disorder,
obsessive-compulsive disorder, phobia, and panic dis-
order. Comorbid substance abuse was the sum (range,
0–3) of the lifetime prevalence of three features: alcohol
abuse or dependence, drug abuse or dependence, and
nicotine dependence.
Obesity was defined as a body mass index (BMI) of
30 kg/m2 or more and extreme obesity as a BMI of
40 kg/m2 or more. The Cumulative Illness Rating Scale
(CIRS) (Linn et al. 1968) was used to assess current or
past medical illness burden. Severity was designated as
follows: 0, none: no impairment from or problem with
that system; 1, mild: current mild or past significant
problem; 2, moderate: impairment interferes with nor-
mal activity; 3, severe: severe problems and/or disabling
impairment and/or hard-to-control chronic problems; 4,
extremely severe: life threatening. The CIRS has been
validated as a measure of medical burden in major de-
pression (Papakostas et al. 2003) and bipolar disorder
Table 1 Demographics of participants in the bipolar disorder
biobank (n = 1363)
Characteristic Valuea
Women 820 (60.2)
Age at enrollment, y 42.6 (14.9)





Education level (n = 1296)
Less than high school 34 (2.6)
High school graduate or GED 166 (12.8)
Some college or higher 1096 (84.6)
Employment (n = 1274)
Working 564 (44.3)
Not currently working for pay 710 (55.7)





GED general educational development tests
aValues are no. of patients (%) or mean (SD)
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den defined as a total CIRS score of 4 or greater. For this
study, the CIRS was modified by removing the “psychi-
atric illness” item, resulting in 13 organ system–oriented
questions. All clinical phenotype is in clinical database
separate from the biospecimens.
Biospecimen collection
Venipuncture was performed using standard techniques.
A total of 45 mL of blood was collected from each par-
ticipant. Blood was drawn into two 10-mL EDTA tubes,
one 10-mL no-additive serum tube, one 10-mL sodium
heparin tube, and one 4.5-mL sodium citrate tube. All
tubes were labeled with a study subject identifier, collec-
tion date, and time of draw. After collection, samples
were electronically accessioned at the Biospecimens
Accessioning Processing Laboratory at the Mayo Clinic
Advanced Genomics Technology Center. Samples under-
went subsequent fractionation, DNA extraction, analysis,
and storage. All disease related biobanks at Mayo Clinic
and the Community Biobank (Olson et al. 2013) have
standardized all procedures for specimen collection,
DNA extraction, serum/plasma processing, and storage
to enable case vs control analyses that are matched for
specimen quality control.
Statistical analysis
Participants’ demographic characteristics obtained from
the participant questionnaire and clinical variables ob-
tained from the SCID and the clinical questionnaire
were described with standard summary statistics. Statis-
tical summaries were prepared using SAS software ver-
sion 9.3 (SAS Institute, Inc).
Results
Among the first 1363 participants enrolled in the bipolar
biobank through September 2014, the racial makeup was
predominantly white (90.6 %), 60.2 % were women, and
the mean (SD) age was 42.6 (14.9) years (Table 1). Al-
though a majority of participants (84.6 %) had attended
at least some college, more than half (55.7 %) were not
currently employed.
The specific diagnoses of the participants were bipolar
disorder I in 69.0 %, bipolar disorder II in 29.2 %, and
schizoaffective bipolar disorder in 1.8 % (Table 2).
Current psychiatric comorbidity was high, most notably
with generalized anxiety disorder (41.4 %), nicotine de-
pendence (26.6 %), panic disorder (20.1 %), social anxiety
disorder (18.9 %), attention deficit hyperactivity disorder
(17 %), posttraumatic stress disorder (16.1 %), alcohol
abuse/dependence (14.1 %), and bulimia/anorexia/binge
eating disorder (2.7 %). Lifetime comorbid conditions
(Table 2) included generalized anxiety disorder (50.7 %),
nicotine dependence (39.8 %), alcohol abuse/dependence(39.1 %), panic disorder (31.3 %), attention deficit hyper-
activity disorder (27.8 %), posttraumatic stress disorder
(26.4 %), social anxiety disorder (24.6 %), and bulimia/
anorexia/binge eating disorder (10.4 %).
At the time of enrollment in the biobank, almost half
the patients had a current or recent depressive episode
(49.8 %) (Table 2). Additional clinical phenotypes in-
cluded history of psychosis (42.3 %), history of one or
more suicide attempts requiring medical attention
(32.5 %), composite score of mood instability (1.5 (1.4)),
comorbid anxiety composite score (1.5 (1.4)), drug ad-
diction composite score (1.0 (1.0)), family history of
completed suicide (11.7 %), and several adverse drug-
related events (antidepressant-induced mania (31.7 %),
tardive dyskinesia (3.2 %), history of drug-related rash
(5.7 %), and serious rash (3.7 %)).
Medical comorbid conditions were substantial. The
total mean (SD) CIRS was 4.1 (3.6) with subsection
mean scores as follows: cardiac, 1.2 (0.6); hypertension,
1.4 (0.7); vascular, 1.2 (0.5); respiratory, 1.4 (0.7); eyes,
ears, nose, throat, 1.4 (0.7); lower gastrointestinal, 1.3
(0.6); upper gastrointestinal, 1.4 (0.7); hepatic, 1.1 (0.3);
renal, 1.1 (0.4); other genitourinary, 1.3 (0.6); musculo-
skeletal, 1.5 (0.8); neurologic, 1.6 (0.8); and endocrine-
metabolic, 1.5 (0.8). A high medical burden (total score
≥4) was present in 47.7 % of participants. A total of 539
Table 2 Clinical characteristics of participants in the bipolar
disorder biobank (n = 1363)
Characteristic Valuea
SCID diagnosis
Bipolar I 941 (69.0)
Bipolar II 398 (29.2)
Schizoaffective bipolar 24 (1.8)
Current or recent depression 679 (49.8)
History of psychosis 563 (42.3)
(n = 1330)
Suicide attempt 436 (32.5)
(n = 1340)
Mood instability
Mean value 1.5 (1.4)
(n = 1333)
Mixed mania 134 (14.0)
(n = 954)




Cycle acceleration 353 (26.5)
(n = 1330)
Increased severity 446 (33.4)
(n = 1336)
Anxiety disorder
Mean value 1.5 (1.4)
(n = 1333)
Posttraumatic stress disorder 345 (26.4)
(n = 1307)
Generalized anxiety disorder 664 (50.7)
(n = 1309)
Social anxiety disorder 319 (24.6)
(n = 1297)




Panic disorder 409 (31.3)
(n = 1306)
Addiction, lifetime
Mean value 1.0 (1.0)
(n = 1342)
Alcohol abuse/dependence 514 (39.1)
(n = 1316)
Nicotine dependence 522 (39.8)
Table 2 Clinical characteristics of participants in the bipolar
disorder biobank (n = 1363) (Continued)
(n = 1313)
History of drug/substance 343 (27.0)
(n = 1271)
BMI (n = 1257)
Mean value, kg/m2 29.91 (6.95)
Overweight 397 (31.6)
Obese 421 (33.5)
Morbid obesity 118 (9.4)
First-degree relative suicide 125 (11.7)
(n = 1067)
Antidepressant-induced mania 247 (31.7)
(n = 779)
Tardive dyskinesia 37 (3.2)
(n = 1167)
Drug-related rash 65 (5.7)
(n = 1147)
Serious rash 9 (3.7)
(n = 246)
BMI body mass index, SCID Structured Interview for DSM-IV
aValues are no. of patients (%) or mean (SD)
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criteria for obesity, with a BMI of 30 kg/m2 or higher
(Fig. 1).
Discussion
This initial evaluation of the demographic and clinical
characteristics of patients with bipolar disorder enrolled
in the Mayo Clinic Bipolar Disorder Biobank suggests a
group with substantial psychiatric and medical comor-
bidity. The demographics and comorbid conditions of
the study sample are representative of the general
population of patients with bipolar disorder and, thus,
potential research findings based on this sample would
be generalizable. For example, the mean age and
depressive-predominant disease are very similar to
those reported in regulatory treatment trials for bipo-
lar depression (McElroy et al. 2010). The percentages
of comorbid anxiety, addiction, and obesity resemble
other published demographics in longitudinal studies from
the Stanley Foundation Bipolar Network (Leverich et al.
2001; Suppes et al. 2001) and the Systematic Treatment
Enhancement Program for Bipolar Disorder (Kogan et al.
2004). The prevalence rates of high medical burden resem-
ble other studies in bipolar disorder (Kemp et al. 2014),
with rates of obesity higher than in the general population
(Ogden et al. 2014).
An important strength of the biobank is the detailed
phenotype obtained for all participants. The detailed
Fig. 1 Body mass index of the participants (n = 1257)
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of mood instability, comorbid anxiety, and multiple drug
addiction, beyond the SCID-confirmed bipolar disorder
subtype—represents novel composite quantifications and
may provide more detailed clinical disease characteristics
that can be used in future biomarker genomic studies.
Our group has already identified risk genes not previ-
ously identified from datasets in the public domain by
narrowing the phenotype from bipolar disorder to a
specific comorbid condition, which in essence decreases
phenotypic (and therefore genetic) heterogeneity (Winham
et al. 2014). We have since replicated these findings using
samples from the Mayo Clinic Biobank (Cuellar-Barboza
et al.). Future studies that focus not on a DSM5 bipolar
disorder diagnosis but on a more detailed phenotype such
as bipolar disorder with obesity may uncover risk genes not
previously identified.
Narrowly defined phenotypes may also provide greater
power in pharmacogenomic studies of treatment re-
sponse or adverse events. An example is The Consortium
for Lithium Genetics, the goal of which is to facilitate
high-quality, well-powered genomic analyses of lithium
treatment response (Schulze et al. 2010) with a narrow
standardized phenotype of prophylactic lithium response
quantified using the Alda Scale (Grof et al. 2002). As
another example, early work from our group focused
on developing a narrowly defined phenotype of
antidepressant-induced mania. Whereas most prior
pharmacogenetic studies of antidepressant-induced
mania focused on association with the s allele of the
promoter region length polymorphism (5-HTTLPR)
in the serotonin transporter gene SLC6A4 (Biernacka
et al. 2012), our group identified a unique SLC6A4
haplotype composed of the 5-HTTLPR, SNP rs25531, and
intron 2 VNTR that was associated with a decreased risk
of this adverse drug event (Frye et al. 2015a). Suchpharmacogenomics studies have the potential to transform
clinical practice. Such transformation has already been seen
with the mood-stabilizing agent carbamazepine, which
underwent a US Food and Drug Administration boxed
warning revision when an association between HLA-
B*1502 and the risk of serious dermatologic adverse effects
(Stevens-Johnson syndrome, toxic epidermal necrolysis)
was identified in persons of Han Chinese descent (Ferrell
and McLeod 2008). The HLA-B*1502 allele was not identi-
fied in other races or ethnicities, but recent data identified
similar HLA antigens, HLA-B*1511 and HLA-A3101, in
Stevens-Johnson syndrome and severe cutaneous reactions
in a Korean population (Kim et al. 2011).
Because of the demographics in the recruitment areas,
the biobank sample currently has little racial and ethnic
variation, being 90 % white. Although this has advan-
tages in terms of reducing heterogeneity in biomarker
studies, new discoveries will need to be confirmed in
other specific or more diverse populations. It will be im-
portant for future studies to analyze replication cohorts,
particularly in study samples of more diverse ancestry.
Our biobank is broadening study sites with a particular
focus on persons with ancestry other than European in
other parts of the USA, as well as in Mexico and Chile.
The biobank data are limited by some retrospective as-
pects of illness quantification and lack of current state-
dependent measures of illness severity. Both of these are
being addressed with a prospective biomarker clinical
trial embedded within the biobank, with rating scales for
depression and mania.
This phenotypically rich resource will continue to en-
roll new subjects and encourage discovery of genomic
and other biomarkers using state-of-the-art research
technology to help stage disease burden and better
individualize treatment selection. The breadth of data
and biospecimen availability (anticipate expansion to
Frye et al. International Journal of Bipolar Disorders  (2015) 3:14 Page 6 of 7RNA and other bio specimen such as CSF) from biobank
participants will provide the opportunity for numerous
and diverse research collaborations with high potential
for clinical translation. In a time of unprecedented
growth in the scope of medical research, which necessitates
increased efficiency, data and samples can no longer be col-
lected for the purpose of performing a single focused study.
Current technologies allow for the measurement of various
blood biomarkers (including DNA genetic variants, metab-
olites, and proteins); this produces high-dimensional data
that allow for a broad range of hypothesis-generating and
hypothesis-testing studies. Large scale collaborative re-
search will need to employ easy to implement information
technology to ensure the success of these research initia-
tives (Demiroglu et al., 2012).
Conclusions
Given the complexities in diagnosing bipolar disorder,
particularly in adolescents and young adults, as well as
high rates of morbidity and mortality, there is great clin-
ical need for improved diagnostics. Genomic medicine
may provide the tools to assist clinicians in making a
diagnosis and increase the likelihood of earlier successful
treatment interventions. Future studies would benefit
from including a unipolar cohort with longitudinal
follow-up to better understand genomic disease-risk pre-
diction. Furthermore, biomarkers of treatment response
may enable clinicians to target the right drug to each pa-
tient, thus, minimizing unsuccessful treatment trials.
Identifying biomarkers can also help with risk stratifica-
tion for adverse events related to various treatments and
enhance drug development, for an increased and indi-
vidualized bipolar pharmacopoeia.
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